TY - JOUR T1 - Recovery from the COVID-19 pandemic by mass vaccination: emergent lessons from the United States and India JF - medRxiv DO - 10.1101/2021.05.26.21257847 SP - 2021.05.26.21257847 AU - Edwin Michael AU - Ken Newcomb AU - Anuj Mubayi AU - Imran Mahmood Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/27/2021.05.26.21257847.abstract N2 - The advent of vaccinations has heightened global optimism that the end of the SARS-CoV-2 pandemic could be in sight. However, concerns, including the impact of variations in the rates of vaccination between countries, raise questions about the use of mass vaccination for accomplishing a quick recovery from the contagion. Here, we used a SEIR-based model calibrated to data on the pandemic and vaccinations reported for the United States (US) and India to gain strategic insights into using mass vaccinations for ending COVID-19. We estimate that while up to 65% of the US population is already immune to the virus due to the recent rapid mass vaccinations carried out, only 13% of the Indian population may be immune currently owing to a slow rate of vaccination and the effect of a stricter lockdown imposed to curb the first wave of the pandemic. We project that due to the higher immune to susceptible ratio already achieved in the US, the pandemic will only decline if the present rates of vaccinations and social mitigations are continued and remain effective. By contrast, the recent loosening of social measures coupled with a slow rate of vaccination is the chief reason for the virus resurgence in India, with only immediate lockdowns coupled with ramping up of vaccinations providing the means to control the present wave. These results highlight that using mass vaccination to achieve a speedy recovery from the SARS-CoV-2 pandemic will depend crucially on the ability to carry out national vaccinations as rapidly as possible.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a modelling study of publically reported data, so no approval or exemption required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe computation system, data and model parameters are available at: https://github.com/EdwinMichaelLab/COVID-SEIR-India https://github.com/EdwinMichaelLab/COVID-SEIR-India ER -